Name: Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD by Oncology Data Advisor® in From the Archives - Expert Perspectives
Duration: 5 min 52 s
Description: In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.

From the Archives -  Expert Perspectives

In honor of Breast Cancer Awareness Month, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and a member of the National Breast Cancer Foundation (NBCF) Medical Advisory Board discusses factors in the risk and prevention of breast cancer. Ms. Shockney shares advice for minimizing one's risk of developing breast cancer and explains the genetic factors that can come into play in the development of this disease.

Breast Cancer Risk Factors and Prevention With Lillie S. Shockney, RN, BS, MAS, HON-ONN-CG

In honor of Breast Cancer Awareness Month, Lillie Shockney RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and a member of the National Breast Cancer Foundation (NBCF) Medical Advisory Board, discusses the genetic factors that come into play in the development of breast cancer. In addition, she shares advice for which individuals should receive genetic testing and when, as well as strategies for counseling individuals who are undergoing genetic testing.

Breast Cancer Genetic Risk and Evaluation With Lillie S. Shockney, RN, BS, MAS, HON-ONN-CG

In her latest Breast Cancer Awareness Month video, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, discusses the importance of undergoing 3D mammography breast cancer screening, as well as the crucial role of breast imaging radiologists in this field.

Importance of 3D Mammogram Screening by Breast Imaging Radiologists With Lillie S. Shockney, RN

In this interview, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and medical advisory council member of the National Breast Cancer Foundation, discusses the pathology of breast cancer, prognostic factors for disease outcomes, and the crucial role of breast pathologists in setting the stage for diagnosis and treatment.

Breast Cancer Pathology and Setting the Stage for Treatment: Lillie Shockney, RN, HON-ONN-CG

For this podcast in honor of Breast Cancer Awareness Month, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation medical advisory council, discusses current standards and recent advances in breast cancer surgery, including lumpectomies, prophylactic mastectomies, and reconstructive procedures.

Understanding Breast Cancer Surgery and Reconstruction: Lillie S. Shockney, RN, BS, MAS, HON-ONN-CG

In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.

Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD

Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians.

Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX

Additional Advances in Genetic Counseling and Testing in Cancer Care With Filipa Lynce, MD, and Catherine Skefos, MA, MS, CGC

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: bit.ly/45u106o

Click here to continue listening to Module 2 of this series: bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care - Module 1

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: bit.ly/3HtOziO

Click here to listen to Module 1 of this series: bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!

Click here to claim you CE credit for this activity: https://bit.ly/45u106o

Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. 

Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!

Click here to claim credit for this activity: https://bit.ly/3HtOziO

Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Last Chance: Multiple Myeloma Task Force Podcast

Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025.

Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma.

Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

EXPIRING SOON! Mitigating Disease Burden and Healthcare Disparities in Multiple Myeloma

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind 

ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool. 

From Abstracts to Action: How ASCOmind Streamlines Oncology Insights With Xiaoyan Wang, PhD; William Oh, MD; and Waqas Haque, MD, MPH

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit: https://bit.ly/488fPhK

Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.

Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!

Click the link to claim your CE credit:

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD

Oncology Data Advisor®

Related tracks